Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen receptors and progesterone receptors (< 1%) and does not overexpress the epidermal growth factor receptor type 2. Almost 10%鈥 20% of breast cancer patients are diagnosed with this type of...
Find all the latest on breast at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer Nirmal Robinson Ruhi Polara Daniel Thomas Research HighlightsOpen Access12 Feb 2025Signal Transduction and Targeted Therapy Volume: 10, P: 52 Immunotherapy boosts responses in hormone receptor-positive breast canc...
Find all the latest on breast cancer treatment at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.
Advancing triple-negative breast cancer treatment through peptide decorated solid lipid nanoparticles for paclitaxel delivery Tahereh Rahdari Mohsen Mahdavimehr S. Mohsen Asghari ResearchOpen Access19 Feb 2025Scientific Reports Volume: 15, P: 6043
German election: a triple crisis looms large at… February 21, 2025 Economy The leadership hack that drives success: Being trustworthy February 21, 2025 Economy US eggs prices hit a record high of… February 13, 2025 Economy Nigeria’s Dangote Refinery to operate at full capacity… ...
Seven natural compounds shown to fight triple negative breast cancer tnbc Sulforaphane from sprouting seeds and egcg from green tea - an effective combination against er ve breast cancer Vitamin D supplementation increases breast cancer and colorectal cancer survival 10 Ways to reduce your oestrogen leve...
在乳腺癌的所有亚型中,三阴性乳腺癌(triple-negative breast cancer,TNBC)和人表皮生长因子受体2(human epidermal growth factor receptor 2 ,HER2)阳性型乳腺癌的恶性程度较高,越来越多的证据提示这两种亚型肿瘤病灶中肿瘤浸润淋巴细胞(tumor-infiltrating lymphocytes,TIL)所占百分比越高,患者的预后越好。但TIL并非单一...
Triple-Negative Breast Cancer Now Has a Targeted Agent On March 8, 2019, the US Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab for first-line treatment of metastatic triple-negative breast... Blog-Breast Cancer-News-Science & Research ...
Dec 11, 2024 Cantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer at San Antonio Breast Cancer Symposium Dec 4, 2024 (R)Cantargia publishes prospectus in connection with rights issue ...